132 related articles for article (PubMed ID: 4332)
21. Effects of L-prolyl-L-leucyl-glycine amide (MIF-I) on dopaminergic neurons.
Kostrzewa RM; Spirtes MA; Klara JW; Christensen CW; Kastin AJ; Joh TH
Pharmacol Biochem Behav; 1976; 5(Suppl 1):125-7. PubMed ID: 13412
[TBL] [Abstract][Full Text] [Related]
22. Does chronic morphine treatment induce a supersensitivity of dopamine receptors in rat brain?
Kuschinsky K
Psychopharmacologia; 1975 Jun; 42(3):225-9. PubMed ID: 1172252
[TBL] [Abstract][Full Text] [Related]
23. Effect of angiotensin on the central action of dopamine.
Braszko J; Wiśniewski K
Pol J Pharmacol Pharm; 1976; 28(6):667-72. PubMed ID: 1034924
[TBL] [Abstract][Full Text] [Related]
24. Pharmacological effects of 1,3-dimethyl-5-aminoadamantane, a new adamantane derivative.
Maj J; Sowińska H; Baran L; Sarnek J
Eur J Pharmacol; 1974 Apr; 26(1):9-14. PubMed ID: 4857604
[No Abstract] [Full Text] [Related]
25. A comparison of the locomotor stimulant properties of amantadine and l- and d-amphetamine in mice.
Thornburg JE; Moore KE
Neuropharmacology; 1972 Sep; 11(5):675-82. PubMed ID: 4151250
[No Abstract] [Full Text] [Related]
26. Stereotyped behaviour patterns and hyperactivity induced by amphetamine and apomorphine after discrete 6-hydroxydopamine lesions of extrapyramidal and mesolimbic nuclei.
Castall B; Marsden CD; Naylor RJ; Pycock CJ
Brain Res; 1977 Mar; 123(1):89-111. PubMed ID: 300267
[TBL] [Abstract][Full Text] [Related]
27. Hypersensitivity of dopamine transmission in the rat striatum after treatment with the NMDA receptor antagonist amantadine.
Peeters M; Page G; Maloteaux JM; Hermans E
Brain Res; 2002 Sep; 949(1-2):32-41. PubMed ID: 12213297
[TBL] [Abstract][Full Text] [Related]
28. Interactions between a novel cholinergic ion channel agonist, SIB-1765F and L-DOPA in the reserpine model of Parkinson's disease in rats.
Menzaghi F; Whelan KT; Risbrough VB; Rao TS; Lloyd GK
J Pharmacol Exp Ther; 1997 Jan; 280(1):393-401. PubMed ID: 8996220
[TBL] [Abstract][Full Text] [Related]
29. Modulation of dopaminergic neurotransmission in the 6-hydroxydopamine lesioned rotational model by peptidomimetic analogues of L-prolyl-L-leucyl-glycinamide.
Ott MC; Mishra RK; Johnson RL
Brain Res; 1996 Oct; 737(1-2):287-91. PubMed ID: 8930377
[TBL] [Abstract][Full Text] [Related]
30. The action of psychotropic drugs on DOPA induced behavioural responses in mice.
Berendsen H; Leonard BE; Rigter H
Arzneimittelforschung; 1976; 26(9):1686-9. PubMed ID: 11809
[TBL] [Abstract][Full Text] [Related]
31. Spectrum of pharmacological actions on brain dopamine. Indications for development of new psychoactive drugs. Discussion of amantadines as examples of new drugs with special actions on dopamine systems.
Randrup A; Mogilnicka E
Pol J Pharmacol Pharm; 1976; 28(6):551-6. PubMed ID: 1034919
[TBL] [Abstract][Full Text] [Related]
32. On some relationships between dopaminergic and serotoninergic mechanisms in pentylenetetrazol convulsions in albino mice.
Lazarova M; Roussinov K
Acta Physiol Pharmacol Bulg; 1979; 5(3):67-74. PubMed ID: 317212
[TBL] [Abstract][Full Text] [Related]
33. Relationships between selective denervation of dopamine terminal fields in the anterior forebrain and behavioral responses to amphetamine and apomorphine.
Fink JS; Smith GP
Brain Res; 1980 Nov; 201(1):107-27. PubMed ID: 7191345
[TBL] [Abstract][Full Text] [Related]
34. Effect of chronic chlorpromazine administration or prior treatment with reserpine on brain apomorphine concentrations and apomorphine-induced sterotyped behaviour in the rat.
Symes AL; Lal S; Young SN; Tsang D; Sourkes TL
Eur J Pharmacol; 1977 May; 43(2):173-9. PubMed ID: 559575
[No Abstract] [Full Text] [Related]
35. Potentiation of apomorphine-induced stereotypies by naloxone and L-prolyl-L-leucyl-glycinamide.
Quock RM; Lucas TS; Hartl TJ
Pharmacol Biochem Behav; 1983 Jul; 19(1):49-52. PubMed ID: 6137836
[TBL] [Abstract][Full Text] [Related]
36. Influence of dopamine-like compounds on stereotypy and locomotor activity in atropinized rats.
Grabowska M
Arch Immunol Ther Exp (Warsz); 1975; 23(6):753-61. PubMed ID: 1241267
[TBL] [Abstract][Full Text] [Related]
37. MIF-1 and its peptidomimetic analogs attenuate haloperidol-induced vacuous chewing movements and modulate apomorphine-induced rotational behavior in 6-hydroxydopamine-lesioned rats.
Castellano JM; Batrynchuk J; Dolbeare K; Verma V; Mann A; Skoblenick KJ; Johnson RL; Mishra RK
Peptides; 2007 Oct; 28(10):2009-15. PubMed ID: 17766011
[TBL] [Abstract][Full Text] [Related]
38. The effect of baclofen and aminooxyacetic acid on the action of drugs stimulating the dopaminergic system.
Sypniewska M
Pol J Pharmacol Pharm; 1978; 30(6):755-66. PubMed ID: 573471
[TBL] [Abstract][Full Text] [Related]
39. Interaction of alpha-MSH and MIF-I with amphetamine on open-field behavior of rats.
Sandman CA; Kastin AJ
Pharmacol Biochem Behav; 1978 Dec; 9(6):759-62. PubMed ID: 34173
[No Abstract] [Full Text] [Related]
40. [Psychopharmacologic spectrum of melanostatin].
Val'dman AV; Kozlovskaia MM; Klusha VE; Svirskis ShV
Biull Eksp Biol Med; 1980 Jun; 89(6):693-6. PubMed ID: 6104996
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
